BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17620857)

  • 1. Pharmacogenomics of statin response.
    Mangravite LM; Krauss RM
    Curr Opin Lipidol; 2007 Aug; 18(4):409-14. PubMed ID: 17620857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics of statin response.
    Mangravite LM; Wilke RA; Zhang J; Krauss RM
    Curr Opin Mol Ther; 2008 Dec; 10(6):555-61. PubMed ID: 19051133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetic determinants of atorvastatin response.
    Rodrigues AC; Hirata MH; Hirata RD
    Curr Opin Mol Ther; 2007 Dec; 9(6):545-53. PubMed ID: 18041665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic predisposition to statin myopathy.
    Vladutiu GD
    Curr Opin Rheumatol; 2008 Nov; 20(6):648-55. PubMed ID: 18946323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
    Harper CR; Jacobson TA
    Curr Opin Lipidol; 2007 Aug; 18(4):401-8. PubMed ID: 17620856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics of statin responsiveness.
    Kajinami K; Akao H; Polisecki E; Schaefer EJ
    Am J Cardiol; 2005 Nov; 96(9A):65K-70K; discussion 34K-35K. PubMed ID: 16291017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy.
    Schmitz G; Schmitz-Madry A; Ugocsai P
    Curr Opin Lipidol; 2007 Apr; 18(2):164-73. PubMed ID: 17353665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics of cholesterol-lowering therapy.
    Schmitz G; Langmann T
    Vascul Pharmacol; 2006 Feb; 44(2):75-89. PubMed ID: 16337220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of statin therapy in patients with preexisting liver disease.
    Onofrei MD; Butler KL; Fuke DC; Miller HB
    Pharmacotherapy; 2008 Apr; 28(4):522-9. PubMed ID: 18363535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipidomics-based safety biomarkers for lipid-lowering treatments.
    Laaksonen R; Jänis MT; Oresic M
    Angiology; 2008; 59(2 Suppl):65S-8S. PubMed ID: 18632766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic determinants of statin intolerance.
    Oh J; Ban MR; Miskie BA; Pollex RL; Hegele RA
    Lipids Health Dis; 2007 Mar; 6():7. PubMed ID: 17376224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characterization and molecular mechanisms of statin myopathy.
    Toth PP; Harper CR; Jacobson TA
    Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):955-69. PubMed ID: 18666846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin myopathies: pathophysiologic and clinical perspectives.
    Baker SK; Tarnopolsky MA
    Clin Invest Med; 2001 Oct; 24(5):258-72. PubMed ID: 11603510
    [No Abstract]   [Full Text] [Related]  

  • 15. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Statin-induced muscular problems are underestimated].
    Ravnskov U
    Ugeskr Laeger; 2010 Apr; 172(16):1235; author reply 1235. PubMed ID: 20437666
    [No Abstract]   [Full Text] [Related]  

  • 17. Statin myopathy as a metabolic muscle disease.
    Phillips PS; Haas RH
    Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):971-8. PubMed ID: 18666847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the mechanisms of statin-induced myopathy.
    Laaksonen R
    Clin Pharmacol Ther; 2006 Jun; 79(6):529-31. PubMed ID: 16765140
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of intensive statin therapy in the elderly.
    Maroo BP; Lavie CJ; Milani RV
    Am J Geriatr Cardiol; 2008; 17(2):92-100. PubMed ID: 18326948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.